Norman LaFrance

Norman LaFrance

Company: PLUS Therapeutics

Job title: Chief Medical Officer


Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers 4:30 pm

Targeted radiotherapeutics for cancer Lead investigational drug: Rhenium-186 NanoLiposome U.S. ReSPECT clinical trials updateRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.